Semaglutide vs Tirzepatide
Ozempic, Wegovy, RybelsusvsMounjaro, Zepbound
Semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) are both once-weekly injectable incretin therapies used for type 2 diabetes and weight management; semaglutide acts on the GLP-1 pathway, while tirzepatide acts on both the GIP and GLP-1 pathways.
Vial summary · compiled from public records
At a glance
Semaglutide
Sold as Ozempic, Wegovy, Rybelsus
- Category
- Weight Loss
- FDA / legal status
- Restricted
- Route
- Subcutaneous, oral
Tirzepatide
Sold as Mounjaro, Zepbound
- Category
- Weight Loss
- FDA / legal status
- Restricted
- Route
- Subcutaneous
Side by side
| Field | Semaglutide | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| FDA / legal status | Restricted | Restricted |
| Evidence tier | FDA Approved | FDA Approved |
| Administration route | Subcutaneous, oral | Subcutaneous |
| Compounding access | Restricted | Restricted |
| Providers on Vial | 28 listed | 23 listed |
| Typical price band | $ to $$ | $ to $$ |
Verified providers offering each
Ranked by Vial Score, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
About each compound
About Semaglutide
A synthetic glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide mimics the incretin hormone GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. The compound also acts on hypothalamic receptors to reduce appetite and food intake. Primary clinical applications include the management of type 2 diabetes mellitus and chronic weight management in individuals with obesity or overweight with weight-related comorbidities.
About Tirzepatide
A synthetic dual agonist peptide, tirzepatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The compound produces significant improvements in glycemic control and body weight reduction. Primary clinical applications include treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.